PeptideTrace
Clinical

New clinical trial registered for Setmelanotide

Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) (NCT07496463) registered on ClinicalTrials.gov. Phase: phase 2. Status: not yet recruiting.